[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"early-detection-of-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:early-detection-of-cancer":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,43,80,109,139,162,196,225,260,282,309,332,356,388,409,437],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100054274","ultrasound-screening-for-early-detection-of-breast-cancer-in-elderly-women-a-mixed-cluster-individual-rct-100054274",false,"NCT07698366","Ultrasound Screening for Early Detection of Breast Cancer in Elderly Women: A Mixed Cluster-Individual RCT","A Multicenter, Open-label, Mixed Cluster-Individual Randomized Controlled Study on the Efficacy of Breast Cancer Ultrasound Screening","Inclusion Criteria:\n\n\\- Female Age 65-80 years Resident in participating community ≥6 months Signed informed consent\n\nExclusion Criteria:\n\n* History of breast cancer Breast screening within past 2 years Severe comorbid conditions affecting survival Acute breast infection Cognitive impairment affecting participation",true,"FEMALE","65 Years","80 Years",{"count":21,"type":22},82440,"ESTIMATED","INTERVENTIONAL",[25],"NA","This multicenter study aims to evaluate whether active breast ultrasound screening can improve the early diagnosis rate of breast cancer in women aged 65 to 80 years, compared with routine elderly health management. The study uses a mixed cluster-individual randomized design based on community implementation capacity. A subgroup of pilot communities will simultaneously collect ultrasound AI data for research performance analysis only, without affecting clinical diagnosis.",[28,29],"Breast Neoplasms","Early Detection of Cancer","NOT_YET_RECRUITING","2026-07-08",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":22},"2026-07-10",{"date":38,"type":22},"2029-12-31",{"name":40,"class":41},"The First Affiliated Hospital with Nanjing Medical University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":16,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":42},"100641780","impact-of-sms-messaging-on-participation-in-colorectal-cancer-screening-100641780","NCT07628998","Impact of SMS Messaging on Participation in Colorectal Cancer Screening","Impact of SMS Notifications on the Colorectal Cancer Screening Program","Inclusion Criteria:\n\n* Women and men aged 50 to 69 years.\n* Residents of the Vallès Occidental area.\n* Individuals invited to the Colorectal Cancer Screening Program (PDPCCR) who have not participated within 5 weeks of the initial invitation.\n\nExclusion Criteria:\n\n* Personal history of colorectal cancer.\n* Inflammatory bowel disease (IBD)\n* Colorectal polyps requiring specific clinical follow-up.\n* Hereditary polyposis syndromes.\n* High-risk family history of colorectal cancer: a first-degree relative diagnosed before age 50, or two or more first-degree relatives at any age.\n* Severe morbidity that precludes the performance of a colonoscopy in the event of a positive test result.","ALL","50 Years","69 Years",{"count":54,"type":22},10084,[25],"Colorectal cancer is a leading cause of mortality in Catalonia. Although early detection programs using the fecal immunochemical test (FIT) are effective in reducing both incidence and mortality, their success relies on high population participation. Currently, in the Vallès Occidental region, the participation rate stands at 42%, which is below the 65% minimum recommended by European health authorities. The objective of this randomized controlled trial is to evaluate whether sending a reminder text message (SMS) is an effective tool to increase participation in the screening program. The study will include 10,084 participants aged between 50 and 69 years. Half of the participants will receive a reminder SMS five weeks after their initial invitation, while the other half will follow the standard of care involving postal letters. Researchers anticipate that this strategy will not only increase the number of individuals undergoing screening but also shorten the response time and reduce the need for sending postal reminders",[58,29],"Colorectal Neoplasms",[60,61,62,63,64,65,66,67,68,69],"Colorectal Cancer Screening","Text Messaging","Fecal Occult Blood Test","Public Health","Patient Participation","Reminder Systems","SMS Reminders","mHealth","Cancer Prevention","Patient Adherence","RECRUITING","2026-06-18",{"date":73,"type":34},"2026-06-22",{"date":75,"type":34},"2026-05-05",{"date":77,"type":22},"2026-12",{"name":79,"class":41},"Corporacion Parc Tauli",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":16,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":42},"100609873","menstrual-cup-for-early-endometrial-cancer-detection-in-lynch-syndrome-100609873","NCT07220239","Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome","Menstrual Cup-based Endometrial Collection as an Alternative to Endometrial Biopsy in Lynch Syndrome Patients","SCREEN-CUP","Pre-pilot study\n\nInclusion criteria:\n\n* Individuals over the age of 18\n* Menstruating\n\nExclusion criteria:\n\n* Levonorgestrel intrauterine device (IUD) in situ or removed within the last 30 days prior to sample collection\n* Patients with prior endometrial ablation\n* Prior history of endometrial cancer or endometrial intraepithelial neoplasia\n* History of germline pathologic germline variant in MLH1, MSH2, MSH6, PMS2, or EPCAM\n* Known allergy against menstrual cup material (silicone)\n\nMain Study Inclusion criteria\n\n* LS carrier with a pathogenic or likely pathogenic germline variant in MLH1, MSH2, MSH6, PMS2, or EPCAM\n* Individuals over the age of 18\n* Planned screening EMB\n* Menstruating\n* Ability to give consent\n\nExclusion criteria:\n\n* Current pregnancy\n* Levonorgestrel IUD in situ or removed within the last 30 days prior to sample collection\n* Patients with prior endometrial ablation\n* Prior history of endometrial cancer\n* Known allergy against menstrual cup material (silicone)","18 Years",{"count":90,"type":22},25,[25],"Study Goal:\n\nThis pilot study wants to find out if using a menstrual cup can be a good, non-invasive way to collect samples from the lining of the uterus (called the endometrium) to help screen for endometrial cancer. This is especially important for women who have a higher chance of getting this cancer, such as those with a genetic condition called Lynch syndrome.\n\nMain Questions the Study Will Answer:\n\n1. Can a menstrual cup collect enough uterine lining (endometrial tissue) for doctors to examine under a microscope?\n2. Are the samples from the menstrual cup as useful for diagnosis as samples taken using the usual method (called an endometrial biopsy or EMB)?\n3. Is using a menstrual cup at home easy, effective, and comfortable for participants?\n4. Can scientists grow small lab models of the uterus (called organoids) from the menstrual cup samples and from biopsy samples?\n\nWhat Will Happen in the Study:\n\n* Participants will use a menstrual cup at home to collect menstrual blood.\n* They will also have a standard endometrial biopsy done by a healthcare provider.\n* After both collections, participants will fill out a short survey about how comfortable and easy it was to use the menstrual cup.\n\nWhat the Study Will Measure:\n\n* Feasibility: How well participants are able to use the menstrual cup and send in the sample.\n* Sample Quality: Whether the menstrual cup collects enough good-quality tissue for testing, and how it compares to biopsy samples.\n* Participant Experience: How women feel about using the menstrual cup, based on the survey.\n* Lab Testing: Whether researchers can successfully grow endometrial organoids from both types of samples.\n\nWhy This Study Matters: If this method works, it could offer a gentler, more convenient way for women to get checked for endometrial cancer-especially those who need regular screening. It could also make it easier to collect samples for research and improve early detection of cancer.",[94,95,96,29],"Endometrial Cancer","Lynch Syndrome","Screening",[94,95,96,98,99],"Early detection","Organoids","2026-06-09",{"date":102,"type":34},"2026-06-10",{"date":104,"type":34},"2025-11-20",{"date":106,"type":22},"2027-03",{"name":108,"class":41},"Jessica D. St. Laurent, MD",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":16,"sex":50,"minAge":4,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":119,"conditions":120,"keywords":123,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":42},"100578508","strategies-to-decentralize-breast-ultrasound-in-rwanda-100578508","NCT06812208","Strategies to Decentralize Breast Ultrasound in Rwanda","Implementation Strategies to Decentralize Breast Ultrasound Services and Facilitate Timely Breast Cancer Diagnoses in Rwanda","Enrollment in this cluster randomized clinical trial will occur at the health facility level.\n\nInclusion Criteria:\n\n1. District hospital in Rwanda;\n2. Already implementing the Women's Cancer Early Detection Program in their districts (i.e. clinicians in health centers and hospitals in the district have received the nationally-sponsored trainings in breast cancer early detection and cervical cancer screening);\n3. Already using the WCEDP electronic medical record in health centers and the district hospital, or prepared to start using it.\n\nExclusion Criteria:\n\n1\\. Already providing routine breast ultrasound in the district hospital.",{"count":117,"type":22},1792,[25],"Diagnosing breast cancer early is critical to reduce preventable breast cancer deaths in sub-Saharan Africa. This can be done in part through increasing patients' access to breast ultrasound, which is essential for evaluating breast masses. However, ultrasound is typically provided only by radiologists at urban referral hospitals. Training clinicians at rural district hospitals who are not radiologists could increase patients' access to breast ultrasound, but strategies to support and supervise these clinicians and ensure they are providing high-quality ultrasound services has not been studied.\n\nThis project will examine the effectiveness and cost of two strategies for training non-radiologist clinicians to perform breast ultrasound in Rwandan district hospitals.",[121,29,122],"Breast Cancer","Ultrasonography",[124,125,126,127,128,129],"breast ultrasound","implementation strategies","low and middle income countries","breast cancer early detection","teleultrasound","Rwanda","2026-06-01",{"date":132,"type":34},"2026-06-02",{"date":134,"type":22},"2027-01",{"date":136,"type":22},"2029-11-30",{"name":138,"class":41},"Brigham and Women's Hospital",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":19,"enrollmentInfo":146,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":42},"100565159","integrating-telehealth-to-advance-lung-cancer-screening-100565159","NCT06638554","Integrating Telehealth to Advance Lung Cancer Screening","ITALCS","Inclusion criteria:\n\nParticipants will be eligible if:\n\n1. are aged 50 to 80\n2. have a history of tobacco use indicated by either: Documented 20 pack-year or greater smoking history in their electronic health record (EHR); OR Self-report via structured survey\n3. currently smoke or formerly smoked cigarettes\n4. have no documented history of lung cancer\n5. have no documented history of lung cancer screening in the 24 months prior to study enrollment\n6. have completed at least one primary care visit at Penn Medicine in the 3 years prior to study enrollment.\n\nExclusion criteria:\n\nParticipants who do not meet inclusion criteria will not be eligible.",{"count":147,"type":22},6000,[25],"The goal of this pragmatic trial is to learn if telehealth strategies can increase shared decision-making (SDM) for lung cancer screening (LCS). It will also learn about the equity of these strategies by conducting non-inferiority analysis by race and sex. The main questions it aims to answer are:\n\n1. Does patient outreach using synchronous and asynchronous telehealth strategies increase completion of SDM visits for LCS?\n2. Is the effectiveness of these telehealth strategies similar by race and sex?\n\nThe study uses a Sequential Multiple Assignment Randomized Trial (SMART) design and includes two stages of interventions. The first stage of intervention includes direct patient outreach with an invitation to schedule either a 1) telehealth SDM visit or 2) telehealth or in-person SDM visit. Participants that do not respond to the first stage interventions receive a text message reminder encouraging SDM visit completion with or without digital care coordination.",[29,151,152],"Telemedicine","Decision Making","2026-05-27",{"date":155,"type":34},"2026-05-29",{"date":157,"type":34},"2024-07-09",{"date":159,"type":22},"2027-06-30",{"name":161,"class":41},"Abramson Cancer Center at Penn Medicine",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":172,"conditions":173,"keywords":176,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":42},"100638338","prospective-sample-collection-study-for-a-blood-based-cfdna-methylation-assay-for-ovarian-cancer-detection-100638338","NCT07593833","Prospective Sample Collection Study for a Blood-Based cfDNA Methylation Assay for Ovarian Cancer Detection","Prospective Clinical Validation Study of a Blood-Based cfDNA Methylation Assay for the Detection of Ovarian Cancer","Inclusion Criteria:\n\n* Female participants.\n* Participants with an ovarian\u002Fadnexal mass who are planned to undergo, for the first time at the current center, surgery or biopsy\u002Fpathologic sampling related to the current lesion, with an expected pathologic diagnosis available as the reference standard.\n* Imaging evaluation during screening suggests a unilateral or bilateral, unilocular or multilocular cystic-solid or solid ovarian\u002Fadnexal mass requiring differential diagnosis.\n* An adequate peripheral blood sample can be collected before the first surgery or before initiation of any systemic anti-tumor treatment for the current ovarian\u002Fadnexal mass, and the sample can be processed and stored within the required time according to the unified study procedures.\n* Clinical data and postoperative pathologic results are expected to be sufficiently complete to provide key information for subsequent analyses.\n* The participant or her legally authorized representative voluntarily signs written informed consent after being fully informed.\n\nExclusion Criteria:\n\n* The participant has already received systemic anti-tumor treatment for the current ovarian\u002Fadnexal lesion under evaluation, such as chemotherapy, targeted therapy, immunotherapy, or radiotherapy, or has already undergone definitive tumor resection or comprehensive staging surgery, and is undergoing surgery only for residual or recurrent lesions.\n* No pathologic diagnosis is ultimately obtained for the current ovarian\u002Fadnexal mass, or no analyzable pathologic conclusion can be established.\n* Imaging findings at screening are highly typical of benign mature cystic teratoma.\n* Ovarian cancer combined with another malignant tumor.\n* There are obvious noncompliances during sample collection, transport, or processing, resulting in severe hemolysis, contamination, or seriously insufficient sample volume, such that the sample cannot meet quality control requirements for cfDNA methylation testing or subsequent analyses.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for enrollment.",{"count":170,"type":22},1000,"OBSERVATIONAL","The goal of this observational study is to learn whether a blood-based cell-free DNA (cfDNA) methylation assay can help detect ovarian cancer, especially early-stage ovarian cancer, in women undergoing clinical evaluation for ovarian tumors or gynecologic diseases. The main questions it aims to answer are:\n\nHow well can this assay distinguish ovarian cancer from benign gynecologic diseases? How accurately can this assay detect early-stage ovarian cancer and other ovarian tumor subtypes?\n\nResearchers will compare the test results from participants with ovarian cancer and participants with benign gynecologic diseases to evaluate the diagnostic performance of the assay.\n\nParticipants will:\n\nProvide blood samples for cfDNA methylation testing Allow researchers to collect clinical and pathological information related to their diagnosis Be grouped according to their final clinical or pathological diagnosis for analysis",[174,175,29],"Ovarian Neoplasms","Ovarian Cancer",[175,174,177,178,179,180,181,182,183,184,185,186],"cfDNA Methylation","Cell-Free DNA","DNA Methylation","Liquid Biopsy","Blood-Based Assay","Early Detection","Biomarker","Early Diagnosis","Diagnostic Performance","Ovarian Tumor","2026-05-12",{"date":189,"type":34},"2026-05-18",{"date":191,"type":22},"2026-07-01",{"date":193,"type":22},"2029-12-30",{"name":195,"class":41},"Tongji Hospital",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":16,"sex":17,"minAge":204,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":23,"phases":207,"briefSummary":208,"conditions":209,"keywords":213,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":222,"locationsCount":224},"100634605","breast-and-cervical-cancer-awareness-training-in-visually-impaired-women-100634605","NCT07541859","Breast and Cervical Cancer Awareness Training in Visually Impaired Women","The Effect of Awareness Education on Breast and Cervical Cancer Screening Among Visually Impaired Women","GORSEM","Eligibility Criteria\n\nInclusion Criteria:\n\n* Women with only a visual impairment (congenital or acquired)\n* Able to communicate, speak, and understand Turkish\n* Voluntarily agree to participate in the study\n* Over the age of 40\n* Have had previous sexual intercourse (Pap smear screening requires sexual activity)\n\nExclusion Criteria:\n\n* Diagnosed with breast or cervical cancer\n* Under the age of 40\n* Have not had sexual intercourse before\n* Have undergone screening for at least one of these two cancer types (breast or cervical) within the last year\n\nAccording to the Turkish Ministry of Health, General Directorate of Public Health, in current screenings conducted in our country, within the breast cancer screening program for women, mammography is recommended every two years for women aged 40-69, and within the cervical cancer screening program, Pap smear and HPV-DNA tests are recommended every five years for women aged 30-65. Since women will be referred by the researchers to KETEM centers after training to undergo mammography and Pap smear screening tests, visually impaired women over the age of 40 who have previously had sexual intercourse will be included in the study, as these two screening tests are performed in this common age group and Pap smear screening requires being sexually active.","40 Years",{"count":206,"type":22},74,[25],"This quasi-experimental study aims to determine whether a breast and cervical cancer awareness training program can increase participation in cancer screening among women with visual impairments. The study also aims to identify barriers to screening and improve knowledge about cancer risk factors and screening methods. The main questions this study will address are:\n\n* Does the training increase the rate at which women with visual impairments attend cancer screening appointments?\n* Does the training improve participants' knowledge about breast and cervical cancer?\n\nParticipants will:\n\n* Receive training on breast and cervical cancer risk factors and screening methods.\n* Learn how to apply to the Cancer Early Diagnosis, Screening, and Training Center.\n* Be encouraged to attend cancer screening during the study period.\n* Have knowledge and screening status assessed before the training, immediately after, and three months later.",[210,28,211,212,29],"Persons With Visual Disabilities","Uterine Cervical Neoplasms","Awareness",[214,215,211,28],"Cancer Screening","Visual Impairment Awareness","2026-04-14",{"date":218,"type":34},"2026-04-21",{"date":220,"type":22},"2026-06",{"date":77,"type":22},{"name":223,"class":41},"Marmara University",2,{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":50,"minAge":88,"maxAge":4,"enrollmentInfo":233,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":235,"conditions":236,"keywords":245,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":259},"100450172","avera-cancer-sequencing-and-analytics-protocol-asap-100450172","NCT05142033","Avera Cancer Sequencing and Analytics Protocol (ASAP)","Implementation of Comprehensive Molecular Profiling and Deep Clinical Annotation of Electronic Health Records in Participants Diagnosed With or at Risk of Developing Cancer (ASAP Study)","ASAP","Inclusion Criteria:\n\n* Must be at least 18 years of age\n* Must be undergoing a workup or being followed for a premalignant condition or have a diagnosis of cancer\n* Must voluntarily sign and understand the most current IRB-approved consent form prior to study participation\n\nExclusion Criteria:\n\n* Participants incapable of understanding the items listed in the consent form and process\n* Participants with a history of or known psychiatric illness deemed unable to consent or adhere to study requirements",{"count":234,"type":22},25000,"The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-based healthcare system. Through comprehensive genomic profiling, investigators aim to identify the underlying genomic drivers of premalignant and malignant conditions across a range of disease stages and cancer types.\n\nComprehensive molecular profiling will include somatic tumor testing (tissue and\u002For blood) using next-generation sequencing. Selected subsets of samples may undergo whole exome and\u002For whole transcriptome sequencing for research purposes. Pharmacogenomic testing will also be performed to better understand individual variability in medication response and to identify opportunities for optimizing treatment. In addition, participants may optionally provide microbiome samples.\n\nTo maximize the value of the genomic data, participants who consent to this protocol will have their electronic health records-both retrospective and prospective-abstracted, curated, annotated, and linked to the genomic data generated through study testing. Given the long-term value of these data, participants may also voluntarily consent to the storage of their biological samples in a biobank and to the use of their de-identified information for future research.\n\nData collected from this participant population will support efforts to advance the understanding of cancer biology, as well as the discovery and validation of biomarkers associated with clinical outcomes. Findings may also be shared through collaborative research initiatives to further promote advancements in cancer research.",[237,238,29,121,239,240,241,242,175,94,243,244],"Cancer","Cancer Diagnosis","Lung Cancer","Colon Cancer","GI Cancer","Gynecologic Cancer","CNS Cancer","Hematologic Cancer",[237,246,247,248,249],"Genomics","Genetics","Microbiome","Pharmacogenomics","2026-03-23",{"date":252,"type":34},"2026-03-27",{"date":254,"type":34},"2021-11-01",{"date":256,"type":22},"2026-12-31",{"name":258,"class":41},"Avera McKennan Hospital & University Health Center",6,{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":50,"minAge":18,"maxAge":4,"enrollmentInfo":267,"targetDuration":269,"studyType":171,"phases":4,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":42},"100354626","strategic-targeting-for-optimal-prevention-of-cancer-100354626","NCT03897374","Strategic Targeting for Optimal Prevention of Cancer","STOP-Cancer","Inclusion Criteria:\n\n* Study subjects may be included in the Clinical Trial if they meet all of the following inclusion criteria:\n\n  * individuals, ages 65 years or older;\n  * must have met medical necessity for hereditary cancer genomic testing and allowed the physician to test based on medical necessity;\n  * hereditary cancer diagnostic test was ordered by a physician related to individual subject care considerations.\n  * study subject has or had cancer\n  * study subject has at least one family member with cirrent or past cancer\n\nExclusion Criteria:\n\n* Study subjects will be excluded from the study if any of the following criteria apply: • study subject is currently hospitalized or incarcerated;\n\n  * study subject is unable to provide an accurate history due to mental incapacity\n  * study subject is currently abusing illicit and\u002For prescription drugs;",{"count":268,"type":22},120000,"120 Days","The primary goal of the study is to record data over the observation period to evaluate the clinical benefit of using hereditary cancer genomic diagnostics to assess overall hereditary genetic cancer risk profile and to help guide physicians to pursue preventative measures, which may lead to early detection and treatment of the condition.",[29],"2026-03-17",{"date":274,"type":34},"2026-03-19",{"date":276,"type":34},"2025-03-26",{"date":278,"type":22},"2028-12-31",{"name":280,"class":281},"ClinLogic LLC","INDUSTRY",{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":16,"sex":50,"minAge":88,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":291,"conditions":292,"keywords":294,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":308},"100170984","caris-biorepository-research-protocol-100170984","NCT01499394","Caris Biorepository Research Protocol","The Caris Biorepository Research Protocol","Inclusion Criteria:\n\n* 18 years of age or older\n* Capacity to provide informed consent\n\nExclusion Criteria:\n\n* Due to the complexity of state and federal requirements governing the participation of prisoners in research, prisoners-patients will not be approached for participation in the Caris Biorepository.\n* Minor subjects will not be included in the Caris Biorepository, as it is possible biospecimens and data may be stored beyond the time limitations of assent and it may be impracticable to re-consent these subjects once they become adults.\n* Individuals who lack the capacity to give informed consent",{"count":290,"type":22},100000,"The Biorepository for Caris Life Sciences is designed for the purpose of making quality biospecimens and associated clinical data available for research studies related to advancing precision medicine and improving care for patients.\n\nThe Caris Biorepository is a repository of prospectively collected biological specimens and associated clinical and demographic data gathered from multiple sources to be stored, used and shared for research. Caris Life Sciences will maintain the data and specimens and will control access to and use of the information and specimens by multiple individuals for multiple purposes which may evolve over time.",[237,29,293],"Minimal Residual Disease",[295,296,182,297,298],"Caris Biorepository","MCED","MRD","Pan-Cancer","2026-01-19",{"date":301,"type":34},"2026-01-21",{"date":303,"type":4},"2010-11",{"date":305,"type":22},"2035-11",{"name":307,"class":281},"Caris Science, Inc.",38,{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":11,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":319,"conditions":320,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":330,"locationsCount":4},"100615907","cervical-cytology-dna-methylation-for-endometrial-lesion-screening-and-follow-up-100615907","NCT07298707","Cervical Cytology DNA Methylation for Endometrial Lesion Screening and Follow-up","A Multicenter Study on Cervical Cytology DNA Methylation for Screening and Follow-up of Endometrial Lesions","EndoMethy-V","Inclusion Criteria:\n\n1. Participants must be 18 years of age or older.\n2. Participants must possess medium-to-high risk factors for endometrial cancer as defined by Chinese consensus guidelines and are scheduled for hysteroscopic evaluation; OR are currently undergoing conservative treatment (e.g., progesterone therapy or endometrial ablation) for endometrial lesions, and have not received chemotherapy.\n3. Participants must be capable and willing to provide written informed consent.\n4. Participants must be willing to undergo at least one follow-up assessment within 1 year.\n5. Participants must have an intact cervix (a history of LEEP or conization is acceptable).\n\nExclusion Criteria:\n\n1. Current treatment for any gynecologic malignancy other than endometrial cancer.\n2. Current or untreated cervical, vaginal, or vulvar intraepithelial neoplasia or carcinoma.\n3. History of total or subtotal hysterectomy, trachelectomy, radical trachelectomy, or pelvic radiotherapy.\n4. Active lower genital tract bleeding.\n5. Immunosuppressed state (e.g., HIV infection, status post organ transplantation).\n6. Failure to undergo the planned hysteroscopic evaluation and follow-up within 1 year after the initial assessment.\n7. Failed hysteroscopic procedure.\n8. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for inclusion in the study.",{"count":318,"type":22},3500,"The goal of this observational study is to evaluate the accuracy of a novel molecular test for screening and monitoring endometrial lesions in women at medium-to-high risk for endometrial cancer.\n\nThe main questions it aims to answer are:\n\n* What is the sensitivity and specificity of the CISENDO test (a DNA methylation test on cervical cytology samples) for detecting histologically confirmed endometrial intraepithelial neoplasia (EIN) or invasive endometrial cancer?\n* How do DNA methylation levels change during the follow-up of endometrial lesions? Researchers will compare the results of the CISENDO test to the results from the standard diagnostic procedure (hysteroscopy with histology) to see if the molecular test can reliably identify high-risk lesions and track disease progression.\n\nParticipants will:\n\n* Provide a residual liquid-based cervical cytology sample for the CISENDO test.\n* Undergo a standard diagnostic hysteroscopy examination (with or without biopsy) for comparison.\n* Some participants will return for follow-up visits at 6 and 12 months for repeat methylation testing and\u002For hysteroscopy to monitor their condition.",[321,179,322,29,323],"Endometrial Neoplasms","Cervical Smears","Endometrial Hyperplasia","2025-12-09",{"date":326,"type":34},"2025-12-23",{"date":328,"type":22},"2026-01-10",{"date":256,"type":22},{"name":331,"class":41},"Peking Union Medical College Hospital",{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":17,"minAge":88,"maxAge":338,"enrollmentInfo":339,"targetDuration":4,"studyType":23,"phases":341,"briefSummary":342,"conditions":343,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":42},"100584663","the-fyi-on-mri-a-multilevel-decision-support-intervention-for-screening-breast-mri-100584663","NCT06892275","The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI","Inclusion Criteria:\n\n* female\n* aged 18-74 years\n* self-identifying as Black and\u002For Latina\n* no personal history of breast cancer\n* English- or Spanish-speaking\n* having received a mammogram with normal results in the last 12 months\n* ≥20% lifetime breast cancer risk per the NCI Breast Cancer Risk Assessment Tool (BCRAT)\n\nExclusion Criteria:\n\n* aged \\\u003C18 or ≥75\n* pregnancy","74 Years",{"count":340,"type":22},80,[25],"The purpose of this study is to test the impact of a multilevel decision support intervention on informed decisions about breast MRI among high-risk Black and Latina women. Participants (N=80) will be randomized to (1) enhanced usual care (risk assessment + referral to nurse practitioner) or (2) decision support (enhanced usual care + decision aid). Assessments will take place at baseline (T0) and 1-month post-intervention (T1). The primary outcome is informed decisions about breast MRI at T1.",[344,29,345,346],"Breast Neoplasm Female","Hereditary Breast and Ovarian Cancer Syndrome","Magnetic Resonance Imaging","2025-09-26",{"date":349,"type":34},"2025-09-30",{"date":351,"type":34},"2025-06-01",{"date":353,"type":22},"2027-12",{"name":355,"class":41},"Georgetown University",{"id":357,"slug":358,"hasResults":11,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":17,"minAge":364,"maxAge":365,"enrollmentInfo":366,"targetDuration":4,"studyType":23,"phases":368,"briefSummary":369,"conditions":370,"keywords":373,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":4},"100608724","ai-based-self-supervised-learning-model-using-non-contrast-breast-mri-for-early-screening-and-clinical-utility-evaluation-100608724","NCT07205276","AI-Based Self-Supervised Learning Model Using Non-Contrast Breast MRI for Early Screening and Clinical Utility Evaluation","Construction of an Early Breast Cancer Screening Warning Model Based on Self-supervised Learning With Plain MRI Scans and Prospective Clinical Utility Evaluation","B-MRI-AI","* Inclusion Criteria:\n\n  1. Female, age 30-70 years\n  2. Completed breast MRI scan, including at least T2WI, DWI, and ADC sequences\n  3. Multimodal data acquired within the same time window (≤90 days)\n  4. A clear clinical outcome: pathologically confirmed or ≥12-24 months of negative follow-up\n  5. The time window between imaging examination and outcome determination was ≤90 days\n  6. Signed informed consent\n* Exclusion Criteria:\n\n  1. Absolute contraindications to MRI (pacemaker, cochlear implant, ocular metal foreign body, etc.)\n  2. Pregnant or lactating women\n  3. Recent history of breast surgery\u002Fradiotherapy (≤6 months) or imaging after neoadjuvant therapy\n  4. Substandard image quality (severe motion artifact, signal-to-noise ratio below threshold)\n  5. Incomplete clinical data or time window exceeded\n  6. Known breast cancer metastasis or recurrence","30 Years","70 Years",{"count":367,"type":22},30000,[25],"Breast cancer is the most common malignant disease among women worldwide, with rising incidence and younger age at onset in China. Early detection is critical for improving survival, yet current screening methods such as mammography and ultrasound show limited sensitivity in Chinese women, particularly those with dense breast tissue. Contrast-enhanced MRI offers higher diagnostic performance but its use is limited by high costs, safety concerns with gadolinium-based contrast agents, and limited accessibility.\n\nThis investigator-initiated trial aims to evaluate the clinical application of non-contrast multiparametric MRI, combined with advanced artificial intelligence algorithms, for the early detection and diagnosis of breast cancer. The study will collect MRI imaging data from multiple centers and integrate radiomic features across T2-weighted imaging, diffusion-weighted imaging, and apparent diffusion coefficient maps. A deep learning-based model will be developed and validated to improve lesion detection, differential diagnosis, and risk stratification.\n\nThe ultimate goal of this project is to establish a safe, accurate, and scalable breast cancer screening pathway suitable for Chinese women. By reducing dependence on invasive procedures and contrast agents, and by leveraging AI for standardization and efficiency, this approach may significantly improve early detection rates and contribute to better patient outcomes.",[371,29,372],"Breast Cancer Detection","AI (Artificial Intelligence)",[374,375,376,377,378],"Breast MRI","Non-contrast MRI","Radiomics","Deep Learning","Breast Cancer Screening","2025-09-25",{"date":381,"type":34},"2025-10-03",{"date":383,"type":22},"2025-10-01",{"date":385,"type":22},"2027-12-01",{"name":387,"class":41},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":11,"sex":50,"minAge":204,"maxAge":395,"enrollmentInfo":396,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":398,"conditions":399,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":42},"100601125","early-screening-cohort-study-of-multiple-gastrointestinal-tumors-100601125","NCT07106424","Early Screening Cohort Study of Multiple Gastrointestinal Tumors","Liquid Biopsy for Early Screening Cohort Study of Multiple Gastrointestinal Tumors","Inclusion Criteria:\n\n* gastrointestinal cancer screening population\n* age 40-75\n* no prior history of tumors\n\nExclusion Criteria:\n\n* Severe heart disease, heart failure;\n* Severe respiratory disease, dyspnea, continuous asthma, or those with serious brain diseases;\n* Severe spinal deformity, or patients with aneurysms;\n* Physically weak and unable to tolerate endoscopy, or those who have difficulty remaining calm and self-controlled;\n* Acute corrosive inflammation of the gastrointestinal tract, or those suspected of having a gastrointestinal perforation;\n* Large amounts of ascites, severe abdominal distension, or severe esophageal varices;\n* Those with a tendency to bleed (abnormal coagulation function), or those taking anticoagulant medications. The latter must discontinue the medication for one week and have normal coagulation function before undergoing endoscopy;\n* Pregnant women;\n* Those with a history of iodine allergy, etc.\n* Patients who have been diagnosed with tumors or have a history of prior tumors.","75 Years",{"count":397,"type":22},4000,"Gastrointestinal tumors, including esophageal cancer, gastric cancer, and colorectal cancer, are among the most common and highly prevalent malignant tumors in Shandong Province. Currently, most patients seek medical attention only after clinical symptoms appear, by which time the disease has already reached an intermediate or advanced stage. This leads to increased treatment costs and poorer therapeutic outcomes. Early detection and intervention through screening are effective measures to improve the cure rate of gastrointestinal tumors and reduce their incidence and mortality rates.\n\nThis project leverages the Shandong Province Tumor Screening and Early Diagnosis \\& Treatment Platform and is based on the ongoing Shandong Gastrointestinal Cancer Screening Cohort. It aims to collect 4,000 plasma samples from individuals undergoing simultaneous screening for esophageal, gastric, and colorectal cancers. Using Nanjing Shihe Medical Laboratory's independently developed multi-cancer early detection liquid biopsy product for gastrointestinal cancers, the study will further validate the performance of liquid biopsy in multi-cancer screening by correlating results with endoscopic findings (gastroscopy and colonoscopy).",[29],"2025-07-30",{"date":402,"type":34},"2025-08-06",{"date":404,"type":34},"2024-09-10",{"date":406,"type":22},"2030-09-10",{"name":408,"class":41},"Shandong Cancer Hospital and Institute",{"id":410,"slug":411,"hasResults":11,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":16,"sex":50,"minAge":204,"maxAge":4,"enrollmentInfo":417,"targetDuration":419,"studyType":171,"phases":4,"briefSummary":420,"conditions":421,"keywords":422,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":42},"100566557","cancerend24-screening-as-an-aid-to-the-clinician-for-the-diagnosis-of-cancer-100566557","NCT06656728","CancerenD24 Screening as an Aid to the Clinician for the Diagnosis of Cancer","Clinical Validation Of A Diagnostic Cancerend24 Screening As An Aid To The Clinician For The Diagnosis Of Cancer In Healthy Subjects Attending The ICPC","CancerenD24","Inclusion Criteria:\n\n1. Completion of all medical exams and questionnaires including cancer diagnoses, demographic data and other epidemiologic information\n2. Willing and able to sign an informed consent\n3. Age ≥40 years\n\nExclusion Criteria:\n\n1. Age \\\u003C 40 years\n2. Pregnancy or breastfeeding\n3. Any type of fever\n4. Any cancer active at study entry or up to 5 years prior to study entry\n5. Polyposis syndromes\n6. Inflammatory bowel disease\n7. Unwilling or unable to provide informed consent",{"count":418,"type":22},2000,"36 Months","The purpose of the researchers is to test whether the CancerenD24 index, an algorithm based on the quantitative value of CD24, CD11b, clinical and laboratory characteristics, developed in the laboratory can help in the early detection of a malignant disease in a population of healthy subjects.",[237,29],[237,98,423,415,424,425,426],"Venous blood sample","CD24","CD11b","Malignant disease","2024-10-23",{"date":429,"type":34},"2024-10-24",{"date":431,"type":34},"2024-09-03",{"date":433,"type":22},"2027-09",{"name":435,"class":436},"Tel-Aviv Sourasky Medical Center","OTHER_GOV",{"id":438,"slug":439,"hasResults":11,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":443,"eligibilityCriteria":444,"healthyVolunteers":16,"sex":50,"minAge":204,"maxAge":395,"enrollmentInfo":445,"targetDuration":4,"studyType":23,"phases":447,"briefSummary":448,"conditions":449,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":457,"locationsCount":42},"100456741","multi-cancer-early-detection-test-in-asymptomatic-individuals-prevent-100456741","NCT05227534","Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)","A Prospective Multi-canceR Early-detection and interVENTional Study in Asymptomatic Individuals: PREVENT","PREVENT","Inclusion Criteria:\n\n* Participants must be able to provide a written informed consent form\n* Participants must not have received any colonoscopy, abdominal MRI\u002FCT, low-dose CT, or chest CT within 5 years before signing the informed consent form\n* Participants must be able to provide blood samples for study tests\n* Participants must be between 40 and 75 years old\n\nExclusion Criteria:\n\n* Individuals who have an acute infection or inflammation within 14 days prior to recruitment\n* Individuals with cancer-associated clinical symptoms or suspected of cancer\n* Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant\n* Recipient of blood transfusion within 7 days prior to recruitment\n* Individuals who have pure ground-glass opacity\n* Unable to provide blood samples for the multi-cancer early detection blood test\n* Individuals who are unable to tolerate standard-of-care cancer screening tests or have contraindications of standard-of-care cancer screening tests\n* Individuals who have taken medication with anti-tumor effects within 30 days prior to recruitment\n* Individuals who have received or are undergoing curative cancer treatment within three years prior to recruitment\n* Individuals with hemorrhagic diseases\n* Individuals with autoimmune diseases\n* Individuals who are pregnant or lactating\n* Individuals who have severe comorbidities that are not suitable for participating in the trial judged by researchers",{"count":446,"type":22},12500,[25],"PREVENT is a prospective, multicenter, interventional study evaluating the performance of the OverC multi-cancer detection blood test in asymptomatic individuals with cancer risk.",[237,29,450],"Circulating Cell-free DNA","2022-06-30",{"date":453,"type":34},"2022-07-06",{"date":455,"type":34},"2022-06-01",{"date":278,"type":22},{"name":458,"class":281},"Guangzhou Burning Rock Dx Co., Ltd."]